Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bydureon
Exenatide LAR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A1 | PLACEBO_COMPARATOR | Placebo lead-in followed by placebo equivalent volume to 0.8 mg exenatide LAR |
| Group A2 | PLACEBO_COMPARATOR | Placebo lead-in followed by placebo equivalent volume to 2.0 mg exenatide LAR |
| Group B | EXPERIMENTAL | Exenatide lead-in followed by exenatide LAR 0.8 mg weekly |
| Group C | EXPERIMENTAL | Exenatide lead-in followed by exenatide LAR 2.0 mg weekly |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg |
| Exenatide LAR | DRUG | Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg. |
Inclusion Criteria: * Has type 2 diabetes treated with either: \*A stable regimen of metformin for a minimum of 3 months, and/or \*Diet modification and exercise for a minimum of 3 months. * Has HbA1c of 7.1% to 11.0%, inclusive. * Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive. Ex...
Exenatide LAR is an investigational therapy being studied for the treatment of Type 2 Diabetes Mellitus. It is designed as a long-acting formulation intended to provide extended glucose-lowering activity in adults with this metabolic condition. It has been evaluated in a Phase 2 clinical trial in the United States.
Exenatide LAR targets GLP1R, the glucagon-like peptide-1 receptor, and acts as a receptor agonist. By activating GLP1R, the drug is designed to mimic the action of the endogenous incretin hormone GLP-1, which supports glucose-dependent insulin regulation in patients with Type 2 Diabetes Mellitus.
Exenatide LAR is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is responsible for advancing this long-acting GLP1R agonist candidate for Type 2 Diabetes Mellitus through clinical development.
Exenatide LAR is in Phase 2 clinical development for Type 2 Diabetes Mellitus. It is an investigational agent and is not approved for commercial use. The Phase 2 program has completed, and no active trials are currently listed for this asset.
Exenatide LAR has been evaluated in one completed Phase 2 trial, NCT00103935, titled "Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes." The trial enrolled 45 participants in the United States, was randomized, double-blind, and placebo-controlled, and included adults aged 18 years and older.